Medicaid Add-On Rebates For Line Extensions Remain A Judgment Call

Manufacturers must continue to use their discretion on which line extensions should be subject to inflation-based Medicaid rebates in lieu of guidance from CMS in its recent AMP final rule.

The Centers for Medicare and Medicaid Services plans to clarify the types of drug line extensions that will be subject to inflation-based add-on rebates in Medicaid after considering further comments from stakeholders.

The agency deferred a final decision on a definition of line extensions in its recent final rule implementing changes to the Medicare drug rebate program under the Affordable Care Act....

More from United States

More from North America